Developer docs
API playgroundTry for free, no card

Search company profiles

GeneFab

Full company profile

uuid0007prq

Namestring
GeneFab
Legal namestring
GeneFab LLC
Websiteurl
genefab.com
Company typeenum
Private
Founded yearint
2023
Descriptiontext

GeneFab is a privately held cell and gene therapy contract research, development, and manufacturing organization (CRDMO) founded in 2023 and headquartered in Alameda, California, with a second site in South San Francisco described as a Synthetic Biology Center of Excellence. The company operates a 42,000 sq ft purpose-built cGMP facility in Alameda (seven Grade B cleanrooms in two segregated wings, expandable to 92,000 sq ft) and serves gene and cell therapy innovators from discovery through commercial supply. Its service portfolio spans Genetic Design (ML-driven sequence and construct design plus proprietary building blocks), Cell Therapy Platforms (autologous and allogeneic manufacturing of CAR-T, TCR-T, CAR-NK, Treg, iPSC and related modalities), Viral Vector Platforms (lentiviral and gamma-retroviral vectors, adherent and suspension, with stable producer cell lines), Cell Banking, Process Development, Analytical & Assay Development, Quality Control & Release, Stability Studies, and Commercial Readiness & Supply.

GeneFab's technical differentiation rests on an integrated synthetic biology and manufacturing stack. Proprietary building blocks include cell-specific synthetic promoters validated across hepatocytes, immune cells, and engineered stem-cell derivatives; drug-induced molecular switches tunable by FDA-approved small molecules; engineered kill switches for selective elimination of modified cells; and ML-driven sequence and construct design that compresses thousands of variants into a clinically tractable set. Manufacturing leverages PBS Vertical Wheel bioreactors (0.1–80 L) combined with XCell ATF perfusion for CAR-NK process intensification, third-generation self-inactivating lentiviral vectors with proprietary cell-specific promoters, and stable producer cell lines designed to improve unit economics at 50–200 L suspension GMP scale.

Commercially, GeneFab operates a project-based professional services revenue model with quote-based pricing under negotiated Project Proposals governed by a Standard Service Agreement, net 30 in USD, alongside multi-year managed-service partnership programs featuring dedicated Program Management Officers, joint steering committees, and cloud-based document sharing. Free consulting services (sequence design, vector selection, antigen design) are bundled to attract and retain program work. Publicly disclosed engagements include a manufacturing agreement covering Phase 1 supply for Senti Biosciences' SENTI-202 and a 2025 partnership with RegCell, supported by research presentations at ASGCT 2024 and CAR-NK process intensification publications in 2025.

Short descriptiontext

GeneFab is a privately held cell and gene therapy CRDMO offering integrated genetic design, cell therapy, and viral vector manufacturing to therapy innovators across discovery through commercial supply, anchored by cGMP facilities in Alameda and South San Francisco.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersAlameda, United States
HQ citystring
Alameda
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
cell therapy manufacturing, gene therapy CDMO, viral vector production, synthetic biology services, GMP manufacturing services
Industry3 codes
PRIMARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAACAK
Gene Therapy Analytical Testing & QC (potency, vg/ddPCR, infectivity, RCL/RCA)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAM
Gene Therapy Regulatory, Pharmacovigilance & Clinical Operations Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Cell & Gene Therapy CDMO Services
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Contract research, development and manufacturing services (CRDMO)
TypeProfessional Services
Description

Custom/contract research, process development, analytical development, cGMP manufacturing and clinical supply services delivered under Project Proposals governed by the Standard Service Agreement. Engagements range from discovery support through IND-enabling, clinical, and commercial supply; project-based with invoices upon completion and acceptance of deliverables, paid in USD within 30 days of invoice. Free consulting services (sequence design, vector selection, antigen design) are bundled at no charge to attract and retain program work.

genefab.com
2Long-term CRDMO partnership programs
TypeManaged Services
Description

Multi-year, integrated development-to-commercial partnerships with dedicated Program Management Officer (PMO), joint steering committee, transparent cloud-based document sharing, and milestone-based billing. Designed to scale from clinical through commercial supply without changing partners, with programs evolving from research-scale exploration to commercial-scale supply.

genefab.com
Cost components5 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Pricing details1 tier
1Custom project-based CRDMO pricing under negotiated Project Proposals
ModelOtherBilling cadenceMulti-year contract
Notes

Quote-based / Not publicly disclosed. Invoiced upon completion and acceptance of Deliverables; net 30 payment terms in USD; 1.5% per month interest accrues on overdue payments; cancellation triggers partial charges for work completed plus authorized incurred expenses. Free consulting on sequence design, vector and cloning site choice, antigen design, and service package selection is included.

genefab.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

GeneFab is an integrated cell and gene therapy Contract Research, Development, and Manufacturing Organization (CRDMO) offering end-to-end services spanning synthetic biology construct design, process and analytical development, cGMP cell therapy and viral vector manufacturing, cell banking, QC release, stability, and commercial supply. The platform combines ML-driven genetic design and proprietary cell-specific promoters and drug-induced switches (South San Francisco) with a 42,000 sq ft cGMP facility featuring seven Grade B cleanroom suites (Alameda) to support autologous and allogeneic cell therapy, lentiviral and gamma-retroviral vectors, and in-vivo gene therapy programs.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

GeneFab is a single integrated cell and gene therapy CRDMO platform rather than a modular SaaS product: each named capability listed above is an in-house service that stitches into one continuous workflow from genetic design through commercial supply, with the same team and same roof spanning the program. The Synthetic Biology / Genetic Design engine in South San Francisco generates the constructs (including the proprietary cell-specific promoters, kill switches, drug-induced switches, and stable producer cell lines) that feed Process Development and Analytical & Assay Development in Alameda; these in turn feed Cell Therapy Platforms and Viral Vector Platforms manufacturing, supported by Cell Banking, cGMP Manufacturing, QC & Release, Stability Studies, and Stability Sample Storage. Rapid Technology Transfer and Integrated GMP Project Teams (with a dedicated PMO) wrap around the technical services to move programs from R&D through IND-enabling, clinical, and Commercial Readiness & Supply without vendor or site handoffs.

Product and service12 records
1Genetic Design
CategorySynthetic Biology Research Service
Description

Synthetic biology research engine providing ML-driven sequence optimization, bioinformatics analysis, high-throughput construct screening, and proprietary building blocks such as cell-specific promoters, kill switches, drug-induced molecular switches, and stable producer cell line engineering for cell and gene therapy innovators.

2Cell Therapy Platforms
CategoryGMP Manufacturing
Description

End-to-end autologous and allogeneic cell therapy manufacturing covering CAR/TCR-T, CAR-NK, Treg, iPSC, aggregate cultures, and other adherent or suspension cell modalities, with expansion on G-Rex, WAVE, and PBS Vertical Wheel (0.1–80 L) platforms, plus cryopreservation, formulation, and fill/finish.

3Viral Vector Platforms
CategoryGMP Manufacturing
Description

Engineered lentiviral (LVV) and gamma-retroviral (GRV) vector manufacturing across adherent (2–20 L) and suspension (1.5–200 L GMP) formats, including transient transfection or stable producer cell lines, multiple envelope pseudotype options, and integrated cell-specific promoters and molecular switches.

4Cell Banking
CategoryStarting Material Services
Description

Engineering, Master, and Working cell bank generation across adherent and suspension platforms, with full release panel (viability, identity, purity, transgene expression, RCV, sterility, mycoplasma, endotoxin, adventitious agents) and in-house irradiated feeder cell generation via qualified X-Rad 320 irradiator.

5Rapid Technology Transfer
CategoryProcess Transfer Services
Description

Structured, risk-based technology transfer methodology covering process, analytical, and quality gap assessments, engineering runs with on-the-floor MSAT, delta analysis, and documented transfer packages, with typical development-to-GMP timelines of ~7 months and commercial-to-commercial up to 24 months.

6Integrated GMP Project Teams
CategoryProgram Management Services
Description

Dedicated cross-functional team and Program Management Officer per program, with transparent Gantt charts, cloud-based document and data sharing, joint steering committees, and routine technical/quality reviews spanning SynBio, process development, analytical, manufacturing, and QC.

7Process Development
CategoryDevelopment Services
Description

Unit operation design, optimization, scale-up, and lock-in for cell therapy and viral vector programs, with on-the-floor MSAT support during engineering runs and cost-of-goods modeling alongside process design.

8Analytical & Assay Development
CategoryDevelopment Services
Description

In-house analytical development covering identity, purity, potency, and safety methods (flow cytometry, dPCR/qPCR, ELISA, Luminex, cytotoxicity, multi-parameter functional assays), with phase-appropriate qualification and validation per USP/EP standards.

9Quality Control & Release
CategoryQuality / Release Services
Description

In-house microbiology and raw material testing (endotoxin, sterility, mycoplasma, environmental monitoring, FTIR identity), full CGT release panel (viability, identity, purity, potency, vector copy number), suitability studies, method validation per USP/EP, and environmental monitoring performance qualification.

10Stability Studies
CategoryQuality / Lifecycle Services
Description

ICH and product-specific stability program design and execution, including real-time, accelerated, and stress studies; in-use, hold-time, and shipping stability; trending and statistical analysis; and shelf-life determination and extension studies.

11Stability Sample Storage
CategoryQuality / Storage Services
Description

GMP-compliant, qualified and temperature-mapped stability chambers with continuous monitoring, controlled ambient, refrigerated, frozen, and ultra-low conditions, secure chain of custody, pull scheduling, and retrieval/shipping support.

12Commercial Readiness & Supply
CategoryLate Stage / Commercial Services
Description

Process performance qualification and BLA-readiness support, with capacity to scale from clinical lots to commercial demand at the Alameda facility (expandable to 92,000 sq ft) without changing CDMO partners.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

One of the largest global CDMOs offering cell therapy manufacturing, viral vector production, and process development across multiple sites. Directly comparable to GeneFab across CAR-T, viral vector, and process intensification services, but operates at vastly greater scale and with established BLA track records.

TypeBroad incumbent
Description

Major CDMO with deep cell therapy and viral vector capabilities following the Paragon acquisition. Directly comparable to GeneFab in lentiviral vector, AAV, and cell therapy manufacturing, though Catalent offers broader fill/finish and global capacity.

TypeDirect peer
Description

CDMO with dedicated cell and gene therapy services including viral vector manufacturing, cell therapy, and process development. Comparable to GeneFab's modality-agnostic CAR/TCR-T, CAR-NK, and iPSC capability set, with similar mid-tier scale.

TypeBroad incumbent
Description

Acquired Cognate BioServices to build a cell and gene therapy CDMO offering, with cGMP cell therapy and viral vector manufacturing. Comparable end-to-end service offering to GeneFab, with stronger analytical and global infrastructure.

TypeDirect peer
Description

Technology-focused biomanufacturing company with cell therapy and viral vector capabilities built around modern, modular facilities. Directly comparable to GeneFab's purpose-built, digitally-minded CDMO positioning for advanced therapies.

TypeBroad incumbent
Description

Operates viral vector and cell therapy manufacturing services as part of its pharma services portfolio. Comparable to GeneFab's lentiviral and gamma-retroviral vector manufacturing capabilities, with broader scale and global reach.

TypeDirect peer
Description

Offers GMP cell therapy manufacturing services alongside its proprietary cell separation and processing instruments. Comparable to GeneFab in CAR-T and engineered cell therapy manufacturing, with deeper integration into upstream cell processing tools.

TypeEmerging player
Description

Cell therapy automation company offering integrated manufacturing platforms (Cell Shuttle) for autologous and allogeneic cell therapies. Comparable to GeneFab's process intensification thesis but differentiated by closed-system automation rather than open-suite GMP.

TypeEmerging player
Description

Early-stage cell therapy manufacturing automation company targeting scalable, cost-effective CGT production. Comparable as a Bay-Area/UK emerging CGT manufacturing technology company with similar modality-agnostic positioning, though focused on automation rather than service-based CDMO.

TypeEmerging player
Description

CDMO offering custom vector design and viral vector manufacturing (LVV, AAV, adenovirus) with research- and GMP-grade offerings. Comparable to GeneFab's integrated vector design + manufacturing proposition, particularly for in-vivo gene therapy programs.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

GeneFab

Cell & Gene Therapy CDMO Servicesgenefab.com

GeneFab is a privately held cell and gene therapy CRDMO offering integrated genetic design, cell therapy, and viral vector manufacturing to therapy innovators across discovery through commercial supply, anchored by cGMP facilities in Alameda and South San Francisco.

What GeneFab does

GeneFab is a privately held cell and gene therapy contract research, development, and manufacturing organization (CRDMO) founded in 2023 and headquartered in Alameda, California, with a second site in South San Francisco described as a Synthetic Biology Center of Excellence. The company operates a 42,000 sq ft purpose-built cGMP facility in Alameda (seven Grade B cleanrooms in two segregated wings, expandable to 92,000 sq ft) and serves gene and cell therapy innovators from discovery through commercial supply. Its service portfolio spans Genetic Design (ML-driven sequence and construct design plus proprietary building blocks), Cell Therapy Platforms (autologous and allogeneic manufacturing of CAR-T, TCR-T, CAR-NK, Treg, iPSC and related modalities), Viral Vector Platforms (lentiviral and gamma-retroviral vectors, adherent and suspension, with stable producer cell lines), Cell Banking, Process Development, Analytical & Assay Development, Quality Control & Release, Stability Studies, and Commercial Readiness & Supply.

GeneFab's technical differentiation rests on an integrated synthetic biology and manufacturing stack. Proprietary building blocks include cell-specific synthetic promoters validated across hepatocytes, immune cells, and engineered stem-cell derivatives; drug-induced molecular switches tunable by FDA-approved small molecules; engineered kill switches for selective elimination of modified cells; and ML-driven sequence and construct design that compresses thousands of variants into a clinically tractable set. Manufacturing leverages PBS Vertical Wheel bioreactors (0.1–80 L) combined with XCell ATF perfusion for CAR-NK process intensification, third-generation self-inactivating lentiviral vectors with proprietary cell-specific promoters, and stable producer cell lines designed to improve unit economics at 50–200 L suspension GMP scale.

Commercially, GeneFab operates a project-based professional services revenue model with quote-based pricing under negotiated Project Proposals governed by a Standard Service Agreement, net 30 in USD, alongside multi-year managed-service partnership programs featuring dedicated Program Management Officers, joint steering committees, and cloud-based document sharing. Free consulting services (sequence design, vector selection, antigen design) are bundled to attract and retain program work. Publicly disclosed engagements include a manufacturing agreement covering Phase 1 supply for Senti Biosciences' SENTI-202 and a 2025 partnership with RegCell, supported by research presentations at ASGCT 2024 and CAR-NK process intensification publications in 2025.

GeneFab firmographics

Firmographics
Name
GeneFab
Legal name
GeneFab LLC
Website
https://genefab.com
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
51–100 employees
Short description
GeneFab is a privately held cell and gene therapy CRDMO offering integrated genetic design, cell therapy, and viral vector manufacturing to therapy innovators across discovery through commercial supply, anchored by cGMP facilities in Alameda and South San Francisco.
Ownership category
akta.pro rank

GeneFab industry classification

Industry
Product category
Cell & Gene Therapy CDMO Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAACAK
Gene Therapy Analytical Testing & QC (potency, vg/ddPCR, infectivity, RCL/RCA)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAM
Gene Therapy Regulatory, Pharmacovigilance & Clinical Operations Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Cell therapy manufacturing
  • Gene therapy CDMO
  • Viral vector production
  • Synthetic biology services
  • GMP manufacturing services

Where GeneFab is headquartered

Location

Headquarters

HQ city
Alameda
HQ country
United States
HQ region
North America

Markets served

GeneFab business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Contract research, development and manufacturing services (CRDMO): Custom/contract research, process development, analytical development, cGMP manufacturing and clinical supply services delivered under Project Proposals governed by the Standard Service Agreement. Engagements range from discovery support through IND-enabling, clinical, and commercial supply; project-based with invoices upon completion and acceptance of deliverables, paid in USD within 30 days of invoice. Free consulting services (sequence design, vector selection, antigen design) are bundled at no charge to attract and retain program work.
  2. Long-term CRDMO partnership programs: Multi-year, integrated development-to-commercial partnerships with dedicated Program Management Officer (PMO), joint steering committee, transparent cloud-based document sharing, and milestone-based billing. Designed to scale from clinical through commercial supply without changing partners, with programs evolving from research-scale exploration to commercial-scale supply.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom project-based CRDMO pricing under negotiated Project Proposals

Go-to-market motion2 records

GeneFab product offering

Product offering

Core offering

GeneFab is an integrated cell and gene therapy Contract Research, Development, and Manufacturing Organization (CRDMO) offering end-to-end services spanning synthetic biology construct design, process and analytical development, cGMP cell therapy and viral vector manufacturing, cell banking, QC release, stability, and commercial supply. The platform combines ML-driven genetic design and proprietary cell-specific promoters and drug-induced switches (South San Francisco) with a 42,000 sq ft cGMP facility featuring seven Grade B cleanroom suites (Alameda) to support autologous and allogeneic cell therapy, lentiviral and gamma-retroviral vectors, and in-vivo gene therapy programs.

Product overview

GeneFab is a single integrated cell and gene therapy CRDMO platform rather than a modular SaaS product: each named capability listed above is an in-house service that stitches into one continuous workflow from genetic design through commercial supply, with the same team and same roof spanning the program. The Synthetic Biology / Genetic Design engine in South San Francisco generates the constructs (including the proprietary cell-specific promoters, kill switches, drug-induced switches, and stable producer cell lines) that feed Process Development and Analytical & Assay Development in Alameda; these in turn feed Cell Therapy Platforms and Viral Vector Platforms manufacturing, supported by Cell Banking, cGMP Manufacturing, QC & Release, Stability Studies, and Stability Sample Storage. Rapid Technology Transfer and Integrated GMP Project Teams (with a dedicated PMO) wrap around the technical services to move programs from R&D through IND-enabling, clinical, and Commercial Readiness & Supply without vendor or site handoffs.

Differentiator

Problem solved

Functional benefit

Products and services

  • Genetic Design Synthetic biology research engine providing ML-driven sequence optimization, bioinformatics analysis, high-throughput construct screening, and proprietary building blocks such as cell-specific promoters, kill switches, drug-induced molecular switches, and stable producer cell line engineering for cell and gene therapy innovators.
  • Cell Therapy Platforms End-to-end autologous and allogeneic cell therapy manufacturing covering CAR/TCR-T, CAR-NK, Treg, iPSC, aggregate cultures, and other adherent or suspension cell modalities, with expansion on G-Rex, WAVE, and PBS Vertical Wheel (0.1–80 L) platforms, plus cryopreservation, formulation, and fill/finish.
  • Viral Vector Platforms Engineered lentiviral (LVV) and gamma-retroviral (GRV) vector manufacturing across adherent (2–20 L) and suspension (1.5–200 L GMP) formats, including transient transfection or stable producer cell lines, multiple envelope pseudotype options, and integrated cell-specific promoters and molecular switches.
  • Cell Banking Engineering, Master, and Working cell bank generation across adherent and suspension platforms, with full release panel (viability, identity, purity, transgene expression, RCV, sterility, mycoplasma, endotoxin, adventitious agents) and in-house irradiated feeder cell generation via qualified X-Rad 320 irradiator.
  • Rapid Technology Transfer Structured, risk-based technology transfer methodology covering process, analytical, and quality gap assessments, engineering runs with on-the-floor MSAT, delta analysis, and documented transfer packages, with typical development-to-GMP timelines of ~7 months and commercial-to-commercial up to 24 months.
  • Integrated GMP Project Teams Dedicated cross-functional team and Program Management Officer per program, with transparent Gantt charts, cloud-based document and data sharing, joint steering committees, and routine technical/quality reviews spanning SynBio, process development, analytical, manufacturing, and QC.
  • Process Development Unit operation design, optimization, scale-up, and lock-in for cell therapy and viral vector programs, with on-the-floor MSAT support during engineering runs and cost-of-goods modeling alongside process design.
  • Analytical & Assay Development In-house analytical development covering identity, purity, potency, and safety methods (flow cytometry, dPCR/qPCR, ELISA, Luminex, cytotoxicity, multi-parameter functional assays), with phase-appropriate qualification and validation per USP/EP standards.
  • Quality Control & Release In-house microbiology and raw material testing (endotoxin, sterility, mycoplasma, environmental monitoring, FTIR identity), full CGT release panel (viability, identity, purity, potency, vector copy number), suitability studies, method validation per USP/EP, and environmental monitoring performance qualification.
  • Stability Studies ICH and product-specific stability program design and execution, including real-time, accelerated, and stress studies; in-use, hold-time, and shipping stability; trending and statistical analysis; and shelf-life determination and extension studies.
  • Stability Sample Storage GMP-compliant, qualified and temperature-mapped stability chambers with continuous monitoring, controlled ambient, refrigerated, frozen, and ultra-low conditions, secure chain of custody, pull scheduling, and retrieval/shipping support.
  • Commercial Readiness & Supply Process performance qualification and BLA-readiness support, with capacity to scale from clinical lots to commercial demand at the Alameda facility (expandable to 92,000 sq ft) without changing CDMO partners.

Companies that use GeneFab

Customer profile

Ideal customer profiles1 record

GeneFab technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature6 records

GeneFab partnerships and signals

Strategic signal

Recent moves6 records

Expansion highlights5 records

GeneFab competitors and assessment

Company assessment

Broad incumbents

  • Lonza Cell & Gene: One of the largest global CDMOs offering cell therapy manufacturing, viral vector production, and process development across multiple sites. Directly comparable to GeneFab across CAR-T, viral vector, and process intensification services, but operates at vastly greater scale and with established BLA track records.
  • Catalent (Paragon Gene Therapy / Biologics): Major CDMO with deep cell therapy and viral vector capabilities following the Paragon acquisition. Directly comparable to GeneFab in lentiviral vector, AAV, and cell therapy manufacturing, though Catalent offers broader fill/finish and global capacity.
  • Charles River Laboratories (Cognate BioServices): Acquired Cognate BioServices to build a cell and gene therapy CDMO offering, with cGMP cell therapy and viral vector manufacturing. Comparable end-to-end service offering to GeneFab, with stronger analytical and global infrastructure.
  • Thermo Fisher Scientific (Viral Vector Services): Operates viral vector and cell therapy manufacturing services as part of its pharma services portfolio. Comparable to GeneFab's lentiviral and gamma-retroviral vector manufacturing capabilities, with broader scale and global reach.

Direct peers

  • AGC Biologics: CDMO with dedicated cell and gene therapy services including viral vector manufacturing, cell therapy, and process development. Comparable to GeneFab's modality-agnostic CAR/TCR-T, CAR-NK, and iPSC capability set, with similar mid-tier scale.
  • Resilience: Technology-focused biomanufacturing company with cell therapy and viral vector capabilities built around modern, modular facilities. Directly comparable to GeneFab's purpose-built, digitally-minded CDMO positioning for advanced therapies.
  • Miltenyi Biotec (Cell Therapy CDMO): Offers GMP cell therapy manufacturing services alongside its proprietary cell separation and processing instruments. Comparable to GeneFab in CAR-T and engineered cell therapy manufacturing, with deeper integration into upstream cell processing tools.

Emerging players

  • Cellares: Cell therapy automation company offering integrated manufacturing platforms (Cell Shuttle) for autologous and allogeneic cell therapies. Comparable to GeneFab's process intensification thesis but differentiated by closed-system automation rather than open-suite GMP.
  • Cellular Origins: Early-stage cell therapy manufacturing automation company targeting scalable, cost-effective CGT production. Comparable as a Bay-Area/UK emerging CGT manufacturing technology company with similar modality-agnostic positioning, though focused on automation rather than service-based CDMO.
  • VectorBuilder: CDMO offering custom vector design and viral vector manufacturing (LVV, AAV, adenovirus) with research- and GMP-grade offerings. Comparable to GeneFab's integrated vector design + manufacturing proposition, particularly for in-vivo gene therapy programs.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

GeneFab social profiles

Digital presence

GeneFab compliance and trust

Trust signal

Compliance3 records

GeneFab financial estimates

Financial estimate

Revenue estimate

Valuation estimate

GeneFab leadership team

Management profile

Number of profiles

Profiles12 records

GeneFab funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

GeneFab M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GeneFab

What does GeneFab do?

GeneFab is an integrated cell and gene therapy Contract Research, Development, and Manufacturing Organization (CRDMO) offering end-to-end services spanning synthetic biology construct design, process and analytical development, cGMP cell therapy and viral vector manufacturing, cell banking, QC release, stability, and commercial supply. The platform combines ML-driven genetic design and proprietary cell-specific promoters and drug-induced switches (South San Francisco) with a 42,000 sq ft cGMP facility featuring seven Grade B cleanroom suites (Alameda) to support autologous and allogeneic cell therapy, lentiviral and gamma-retroviral vectors, and in-vivo gene therapy programs.

Is GeneFab a public or private company?

GeneFab is a private company. It is classified as venture growth investor backed and is currently operating.

When was GeneFab founded?

GeneFab was founded in 2023. It employs 51 to 100 people.

Where is GeneFab based?

GeneFab is headquartered in Alameda, United States, in the North America region.

How does GeneFab make money?

Two revenue lines are on record. Contract research, development and manufacturing services (CRDMO) is the primary driver. The others are long-term CRDMO partnership programs.

Who are GeneFab's main competitors?

Broad incumbents on record are Lonza Cell & Gene, Catalent (Paragon Gene Therapy / Biologics), Charles River Laboratories (Cognate BioServices) and Thermo Fisher Scientific (Viral Vector Services). Direct peers are AGC Biologics, Resilience and Miltenyi Biotec (Cell Therapy CDMO). Emerging players are Cellares, Cellular Origins and VectorBuilder.

Does GeneFab have an API?

No public API is recorded for GeneFab.

What industry is GeneFab in?

GeneFab's product category is Cell & Gene Therapy CDMO Services. Its primary akta.pro industry code is HLAGABAE, Gene Therapy (Viral Vector/Plasmid) CDMO, with a secondary code of HLAAACAK, Gene Therapy Analytical Testing & QC (potency, vg/ddPCR, infectivity, RCL/RCA). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business PageAxiom Biosciences Expands Manufacturing and Clinical Development Capabilities Through Partnership with GeneFabAxiom Biosciences announced a partnership with GeneFab to expand its manufacturing and clinical development capabilities. The collaboration will provide scalable, reproducible production processes for Axiom's therapeutic candidates. The partnership aims to support Axiom's pipeline progression across its lead programs.BioProcess InternationalAdvancing Cell Therapy with Process IntensificationRepligen and GeneFab presented findings on using perfusion technology with XCell ATF devices to enhance the production efficiency of allogeneic cell therapies during a November 2025 webinar. The reported studies demonstrated that perfusion methods significantly increase cell yield, reduce facility footprint, and shorten production times compared to traditional fed-batch processes. Specific collaborations involving Sartorius and Lonza further validated these benefits in scaling CAR-T and CAR-NK cell expansions.BioSpaceGeneFab Launches Cell-Specific Synthetic Promoters and Drug-Induced Switches to Enhance the Safety and Efficacy of in vivo Cellular TherapiesGeneFab announced the launch of pre-validated cell-type specific synthetic promoters and drug-induced switches for in vivo cellular therapies. The products are validated in primary human T cells and off-target types, enabling precise gene expression control and reduced toxicity risk. The launch aims to support adaptive dosing and improve translation for cell and gene therapies.Business InsiderSenti Biosciences Faces Financial Challenges Amid Strategic FocusSenti Biosciences reported a Q3 2024 net loss of $28.9 million, up from $14.9 million a year earlier, with no revenue. Cash and cash equivalents fell to $10.5 million from $35.9 million at year-end 2023. The company divested its non-oncology business to GeneFab and is seeking additional funding.GlobeNewswireGeneFab Announces Two Presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 2024GeneFab announced two poster presentations at the ASGCT 27th Annual Meeting in Baltimore, May 7-11, 2024. The presentations cover a novel gene expression regulation method using FDA-approved small molecules and synthetic promoters for macrophage control. The company's booth is at #1641.GenengnewsGeneFab Subleases Senti Biosciences cGMP FacilityGeneFab has entered into an agreement to sublease Senti Biosciences' cGMP facility in Alameda, California, and acquire its chemistry, manufacturing, and controls (CMC) capabilities for approximately $38 million. The deal enables GeneFab to support the clinical manufacturing of Senti Bio’s off-the-shelf CAR-NK pipeline while employing approximately 50 specialists in cell therapy and synthetic biology.ContractpharmaGeneFab to Sublease Senti Biosciences cGMP FacilityGeneFab will sublease Senti Biosciences' cGMP facility in Alameda, CA, and acquire its CMC capabilities for about $38 million. The company will employ roughly 50 people and support Senti Bio's CAR-NK pipeline via a service contract. Philip Lee will become GeneFab's CEO.GenengnewsGeneFab Subleases Senti Biosciences cGMP FacilityGeneFab signed an agreement to sublease Senti Biosciences' cGMP facility in Alameda, CA, and acquire its CMC capabilities for about $38 million. The 92,000 ft2 facility includes 42,000 ft2 for Phase I/II clinical trial materials, and GeneFab will employ about 50 people.FinancialContent Business PageSenti Bio Announces Second Quarter 2023 Results and Pipeline UpdatesSenti Biosciences announced its second quarter 2023 financial results, reporting a net loss of $18.7 million and holding $59.6 million in cash as it advances its oncology pipeline. The company established a new clinical manufacturing partner, GeneFab, through a transaction that includes approximately $38 million in future payments to Senti Bio, extending its cash runway into the fourth quarter of 2024. Additionally, Senti Bio is finalizing an Investigational New Drug application for SENTI-202, potentially the first Logic Gated CAR-NK treatment for AML, with clinical trials expected to begin in 2024.GlobeNewswireGeneFab Launches to Offer Innovative Manufacturing and Synthetic Biology Design Services for a Broad Range of Genetic MedicinesGeneFab acquired Senti Bio's cGMP facility and CMC capabilities for about $38 million, with Philip Lee becoming CEO. The Alameda facility, built in 2021, supports cell and gene therapy manufacturing, including CAR-NK cell production. GeneFab will employ about 50 people and support Senti Bio's pipeline.